Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
